The AJMC® Type 1 Diabetes compendium is a comprehensive resource for news and interviews about this chronic autoimmune condition.
February 5th 2026
The FTC first sued Express Scripts, CVS Caremark, and Optum in 2024, claiming anticompetitive and unfair rebating practices surrounding insulin.
Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care
1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health
View More
Payment for Pharmacist Services: 2025 Update
1.0 Credit / General Pharmacy, Health Equity, Diversity & Inclusion, Law
View More
Female Adolescents With T1D Have Lower Quality of Life Than Male Children
January 27th 2023A systematic review evaluating sex differences in children with type 1 diabetes (T1D) found that female children had higher rates of comorbidities, higher body mass index, required higher insulin doses, and had a lower quality of life compared with male children.
Read More
T1D Community Helped Create T1D Index, Says JDRF's Tom Robinson
December 17th 2022Tom Robinson, vice president of global access at JDRF, talks about how the community and people living with type 1 diabetes (T1D) have contributed to the T1D Index, from development to publication and going forward.
Watch
T1D Index Will Be Updated Annually, JDRF’s Tom Robinson Explains
November 24th 2022Updating the Type 1 Diabetes (T1D) Index each year with the latest data and literature and implementing feedback is important for at least the first few years, said Tom Robinson, vice president of global access at JDRF.
Watch
JDRF's Tom Robinson Expands on Policies to Ensure Implementation, Access to Key T1D Interventions
November 19th 2022Get type 1 diabetes (T1D) communities involved in solving the problem and implementing T1D interventions in your country, said Tom Robinson, vice president of global access at JDRF.
Watch
JDRF's Tom Robinson Highlights Key T1D Interventions
November 16th 2022While each country has a different priority when it comes to type 1 diabetes (T1D) diagnosis and treatment, there is a fairly consistent outcomes checklist across nations, said Tom Robinson, vice president of global access at JDRF.
Watch
Study Details Effects of Off-Label GLP-1 RA, SGLT2 Inhibitor Use in Type 1 Diabetes
November 9th 2022An analysis of real-world data from a single medical center is providing insight into the effects of off-label glucagon-like peptide 1 (GLP-1) receptor agonist (RA) and sodium-glucose cotransporter-2 (SGLT2) inhibitor use in people with type 1 diabetes.
Read More
JDRF's Tom Robinson Talks About Goals, Reasoning Behind T1D Index
October 18th 2022According to Tom Robinson, vice president of global access at JDRF, the creation of the Type 1 Diabetes (T1D) Index was prompted by a lack of basic data on the condition, such as how many people are living with and affected by T1D.
Watch